Clinical Trials · NCT03884075
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Enrollment
- 104
- Start date
- Jul 2019
- Locations
- 1 site, United States
- Primary endpoint
- Histological Improvement